435 related articles for article (PubMed ID: 19214216)
1. Species-specific activity of HIV-1 Vpu and positive selection of tetherin transmembrane domain variants.
McNatt MW; Zang T; Hatziioannou T; Bartlett M; Fofana IB; Johnson WE; Neil SJ; Bieniasz PD
PLoS Pathog; 2009 Feb; 5(2):e1000300. PubMed ID: 19214216
[TBL] [Abstract][Full Text] [Related]
2. Species-specific activity of SIV Nef and HIV-1 Vpu in overcoming restriction by tetherin/BST2.
Jia B; Serra-Moreno R; Neidermyer W; Rahmberg A; Mackey J; Fofana IB; Johnson WE; Westmoreland S; Evans DT
PLoS Pathog; 2009 May; 5(5):e1000429. PubMed ID: 19436700
[TBL] [Abstract][Full Text] [Related]
3. Mutation of a single residue renders human tetherin resistant to HIV-1 Vpu-mediated depletion.
Gupta RK; Hué S; Schaller T; Verschoor E; Pillay D; Towers GJ
PLoS Pathog; 2009 May; 5(5):e1000443. PubMed ID: 19461879
[TBL] [Abstract][Full Text] [Related]
4. Functional antagonism of rhesus macaque and chimpanzee BST-2 by HIV-1 Vpu is mediated by cytoplasmic domain interactions.
Yoshida T; Koyanagi Y; Strebel K
J Virol; 2013 Dec; 87(24):13825-36. PubMed ID: 24109238
[TBL] [Abstract][Full Text] [Related]
5. Ancient adaptive evolution of tetherin shaped the functions of Vpu and Nef in human immunodeficiency virus and primate lentiviruses.
Lim ES; Malik HS; Emerman M
J Virol; 2010 Jul; 84(14):7124-34. PubMed ID: 20444900
[TBL] [Abstract][Full Text] [Related]
6. Counteraction of tetherin antiviral activity by two closely related SIVs differing by the presence of a Vpu gene.
Nikovics K; Dazza MC; Ekwalanga M; Mammano F; Clavel F; Saragosti S
PLoS One; 2012; 7(4):e35411. PubMed ID: 22530020
[TBL] [Abstract][Full Text] [Related]
7. Vpu of a Simian Immunodeficiency Virus Isolated from Greater Spot-Nosed Monkey Antagonizes Human BST-2 via Two AxxxxxxxW Motifs.
Yao W; Yoshida T; Hashimoto S; Takeuchi H; Strebel K; Yamaoka S
J Virol; 2020 Jan; 94(2):. PubMed ID: 31666374
[TBL] [Abstract][Full Text] [Related]
8. The transmembrane domain of BST-2 determines its sensitivity to down-modulation by human immunodeficiency virus type 1 Vpu.
Rong L; Zhang J; Lu J; Pan Q; Lorgeoux RP; Aloysius C; Guo F; Liu SL; Wainberg MA; Liang C
J Virol; 2009 Aug; 83(15):7536-46. PubMed ID: 19474106
[TBL] [Abstract][Full Text] [Related]
9. Anti-tetherin activities in Vpu-expressing primate lentiviruses.
Yang SJ; Lopez LA; Hauser H; Exline CM; Haworth KG; Cannon PM
Retrovirology; 2010 Feb; 7():13. PubMed ID: 20167081
[TBL] [Abstract][Full Text] [Related]
10. Vpu directs the degradation of the human immunodeficiency virus restriction factor BST-2/Tetherin via a {beta}TrCP-dependent mechanism.
Douglas JL; Viswanathan K; McCarroll MN; Gustin JK; Früh K; Moses AV
J Virol; 2009 Aug; 83(16):7931-47. PubMed ID: 19515779
[TBL] [Abstract][Full Text] [Related]
11. Determinants of tetherin antagonism in the transmembrane domain of the human immunodeficiency virus type 1 Vpu protein.
Vigan R; Neil SJ
J Virol; 2010 Dec; 84(24):12958-70. PubMed ID: 20926557
[TBL] [Abstract][Full Text] [Related]
12. The transmembrane domain of HIV-1 Vpu is sufficient to confer anti-tetherin activity to SIVcpz and SIVgor Vpu proteins: cytoplasmic determinants of Vpu function.
Kluge SF; Sauter D; Vogl M; Peeters M; Li Y; Bibollet-Ruche F; Hahn BH; Kirchhoff F
Retrovirology; 2013 Mar; 10():32. PubMed ID: 23514615
[TBL] [Abstract][Full Text] [Related]
13. Identification of amino acids in the human tetherin transmembrane domain responsible for HIV-1 Vpu interaction and susceptibility.
Kobayashi T; Ode H; Yoshida T; Sato K; Gee P; Yamamoto SP; Ebina H; Strebel K; Sato H; Koyanagi Y
J Virol; 2011 Jan; 85(2):932-45. PubMed ID: 21068238
[TBL] [Abstract][Full Text] [Related]
14. Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu.
Neil SJ; Zang T; Bieniasz PD
Nature; 2008 Jan; 451(7177):425-30. PubMed ID: 18200009
[TBL] [Abstract][Full Text] [Related]
15. In COS cells Vpu can both stabilize tetherin expression and counteract its antiviral activity.
Waheed AA; Kuruppu ND; Felton KL; D'Souza D; Freed EO
PLoS One; 2014; 9(10):e111628. PubMed ID: 25360760
[TBL] [Abstract][Full Text] [Related]
16. HIV-1 Vpu neutralizes the antiviral factor Tetherin/BST-2 by binding it and directing its beta-TrCP2-dependent degradation.
Mangeat B; Gers-Huber G; Lehmann M; Zufferey M; Luban J; Piguet V
PLoS Pathog; 2009 Sep; 5(9):e1000574. PubMed ID: 19730691
[TBL] [Abstract][Full Text] [Related]
17. Antagonism of CD317 restriction of human immunodeficiency virus type 1 (HIV-1) particle release and depletion of CD317 are separable activities of HIV-1 Vpu.
Goffinet C; Homann S; Ambiel I; Tibroni N; Rupp D; Keppler OT; Fackler OT
J Virol; 2010 Apr; 84(8):4089-94. PubMed ID: 20147395
[TBL] [Abstract][Full Text] [Related]
18. Polarity changes in the transmembrane domain core of HIV-1 Vpu inhibits its anti-tetherin activity.
Lv M; Wang J; Wang X; Zuo T; Zhu Y; Kong W; Yu X
PLoS One; 2011; 6(6):e20890. PubMed ID: 21674066
[TBL] [Abstract][Full Text] [Related]
19. HIV-1 Vpu Antagonizes CD317/Tetherin by Adaptor Protein-1-Mediated Exclusion from Virus Assembly Sites.
Pujol FM; Laketa V; Schmidt F; Mukenhirn M; Müller B; Boulant S; Grimm D; Keppler OT; Fackler OT
J Virol; 2016 Aug; 90(15):6709-6723. PubMed ID: 27170757
[TBL] [Abstract][Full Text] [Related]
20. The Ebola virus glycoprotein and HIV-1 Vpu employ different strategies to counteract the antiviral factor tetherin.
Kühl A; Banning C; Marzi A; Votteler J; Steffen I; Bertram S; Glowacka I; Konrad A; Stürzl M; Guo JT; Schubert U; Feldmann H; Behrens G; Schindler M; Pöhlmann S
J Infect Dis; 2011 Nov; 204 Suppl 3(Suppl 3):S850-60. PubMed ID: 21987761
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]